Adimab
PrivateLast Round
Secondary
Feb 6, 2015
Est. Valuation
$1.1B
Total Funding Raised
$39.18M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Adimab operates in Healthcare & Life Sciences and is based in Lebanon, New Hampshire. Its latest recorded funding round was a Series F round in April 2012.
Adimab is a biotechnology company that provides a proprietary yeast-based platform for the discovery, maturation, and engineering of therapeutic human antibodies for pharmaceutical and biotechnology partners.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adimab Comparables
Compare Adimab with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alloy Therapeutics | 86% | |
| AbCellera Biologics Inc. | 86% | |
| OmniAb Inc. | 84% |
For institutional investors. Book with your work email.
Adimab Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Secondary | Feb 6, 2015 | ||||
| Series F | Apr 3, 2012 | ||||
| Series E | Nov 22, 2010 | ||||
| Series D | Oct 1, 2009 | ||||
| Series C | Nov 21, 2008 | ||||
Series B | Mar 25, 2008 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Adimab Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series C, Series D, Series F, Series E, Series A, Series B |
| GV | Series F, Series E, Series D |
| InterWest Partners | Series C |
| Fidelity Management & Research Company | Secondary |
| OrbiMed | Series C, Series D, Series F, Series E |
| Endeavor Venture Funds | Series C |
| Fidelity Investments | Secondary |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 133% MoM, reaching 7.6K.
- Mar 18, 2026
Therapeutic candidate completed Phase 1a trial with partner Gates MRI.
For institutional investors. Book with your work email.
Adimab Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Adimab's valuation, stock price, and market status.
Is Adimab a public or private company?
Adimab is a private company.
What is the current stock price of Adimab?
Adimab is a private company, so its shares have no public market price. Caplight tracks Adimab's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Adimab worth (valuation)?
Adimab's valuation is estimated at $1.1B based on funding round data.
Can I buy Adimab stock?
Adimab shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Adimab's last funding round?
Adimab's most recent funding round was Secondary on February 6, 2015.
Who are the main investors in Adimab?
Key investors in Adimab include SV Health Investors, GV, Polaris Partners.
Will Adimab IPO soon?
No public IPO plans have been announced for Adimab.
How can I track Adimab secondary market activity?
Caplight tracks bids, offers, and trades in Adimab's shares on secondary markets.